Investments in science and technology innovation are emerging as a pivotal determinant influencing brokerage performance. With a steady influx of high-caliber technology firms onto the capital market, brokerages are proactively participating in sci-tech innovation investments via their alternative investment arms and private equity divisions, establishing a robust presence within the sci-tech innovation landscape. Semi-annual report statistics reveal that among the 43 A-share listed brokerages, 36 alternative subsidiaries and 34 private equity subsidiaries have turned a profit. Top-tier brokerages, including Guotai Junan Securities Zhengyu Investment and the alternative subsidiary of China Merchants Securities, have distinguished themselves, with net profits soaring to RMB 6.507 billion and RMB 5.22 billion, respectively. Concurrently, the alternative subsidiaries of CITIC Securities, CSC Financial, and others have also reported significant profit margins. Despite the substantial capital requirements of alternative investment operations, they offer a pathway for smaller brokerages to gain a competitive foothold. Regarding capital allocation, there is a broad agreement on boosting investments in cutting-edge technology sectors, with CITIC Securities Investment expanding its portfolio to include numerous projects in semiconductors and artificial intelligence. Private equity subsidiaries also serve as a crucial channel for brokerages' sci-tech innovation investments, with entities like Guotai Haitong Kaiyuan achieving notable net profits. Both the alternative and private equity subsidiaries of brokerages possess unique strengths in sci-tech innovation investments, collectively forging a vital front for brokerages to support technological innovation.